Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. More recently, AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact.
Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact.
Location: United States, California, Sunnyvale
Employees: 1-10
Phone: +1 415-688-4484
Total raised: $8M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | MBC BioLab... | mbcbiolabs... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.04.2015 | - | $5M | - |
| 17.11.2014 | - | $3M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.04.2022 | Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities | Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April ... |
| 27.04.2015 | Amarantus Bio Raises $5M | - |
| 30.09.2013 | NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership | The test monitors the eyes of seniors as they view a series of image pairs on a computer screen. It tracks how eyes respond to novel and repeat images shown on the screen — healthy patients tend to gravitate more toward novel images, wherea... |
| - | NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership | What if a simple computer test administered in a doctor’s office could foretell which seniors would develop Alzheimer’s disease down the road? Startup NeuroTrack is working toward that, and now a few notable investors have joined in. NeuroT... |